Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

K-Dur 20 – CAFC: Pay-for-delay is “prima facie evidence of an unreasonable restraint of trade.”: In re K-Dur Antitrust Litigation (KEI) (Out-Law) (Patent Docs)

Circadin (Melatonin) – EU: Supplementary Protection Certificates for new uses – CJEU clarifies “first authorization of the product”: Neurim Pharmaceuticals v The Comptroller-General of Patents(The IP Factor) (IPKat) (Beeser Law Professional Corporation) (IPKat) (The SPC Blog) (The SPC Blog)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Is continuous processing in Pharma’s future? (Profitability Through Simplicity)

Australia: Pharmaceutical extensions of term: Is it time for a fix? (Patentology)

China: Growth in China helps keep Novartis from the patent cliff (IAM)

EU: Challenge to the scope of CPVO discretion misconceived and overly formalistic (pontentially) – AG Mazak’s opinion in C-534/10 P Brookfield New Zealand Ltd v Community Plant Variety Office (IPKat)

EU: District Court of The Hague asks CJEU whether sub c of Art 3 precludes grant of SPC for more than one product covered by the same base patent: Georgetown / Queensland (EPLAW)

India: Lack of transparency in domestic policies harming the pharmaceutical sector? The industry speaks out (Spicy IP)

India: Patent evergreening in India: Response from the other side (BIOtechNOW)

Jordan: Access to medicines and intellectual property in Jordan (IP Watch)

US: Federal Circuit hears oral arguments in AMP v USPTO remand (Patent Docs) (Pharma Patents) (KEI)

US: Supplemental brief for appellees in AMP v USPTO (Patent Docs)

US: Myriad Genetics files supplemental brief in AMP v USPTO (Patent Docs)

US: Myriad’s gene patent case receives an amicus curiae brief by Nobel Laureate Dr. James D. Watson (Spicy IP)

US: FDA issues draft guidance expanding pre-IDE to pre-submission program (FDA Law Blog)

US: Evidence of defendant’s intent to discontinue sales of accused product excluded as irrelevant to reasonable royalty analysis: Monsanto v E I Dupont De Nemours (Docket Report)

 

Products

Arava (Leflunomide) – Australia: FCAFC: Extended monopoly on Arava upheld on appeal: Apotex v Sanofi (Patentology) (ipwars.com)

Circadin (Melatonin) – EU: Supplementary Protection Certificates for new uses – CJEU clarifies “first authorization of the product”: Neurim Pharmaceuticals v The Comptroller-General of Patents(The IP Factor) (IPKat) (Beeser Law Professional Corporation) (IPKat) (The SPC Blog) (The SPC Blog)

Combigan (Brimonide, Timolol) – Canada: Allergan v Canada (Health) – Comity or tragedy? (IP Osgoode)

Desmopressin – Germany: BHG addresses incomplete knowledge and prior use rights: X ZR 131/09 (PatLit)

Fortamet (Metformin) – US: Shionogi files patent infringement suit against Nostrum in response to Para IV challenge (Patent Docs)

K-Dur 20 – CAFC: Pay-for-delay is “prima facie evidence of an unreasonable restraint of trade.”: In re K-Dur Antitrust Litigation (KEI) (Out-Law) (Patent Docs)

Lipitor (Atorvastatin) – UK: EWHC (Ch) denies application to make reference to the CJEU for preliminary ruling on interpretation of  Reg 469/2009: Dr Reddy’s & Anor v Warner-Lambert (IPKat)

Memorit (Donepezil) – Israel: Petach Tikveh (Central) District Court rules herbal remedy for same health condition may not be branded MEMORIX and awards damages to Unipharm (The IP Factor)

Prandin (Repaglinide) – US: Supreme Court confirms that generic drug manufacturers can challenge brand-name use-code descriptions in patent litigation: Caraco v Novo Nordisk (Intellectual Property Law Blog)

Reclast and Zometa (Zoledronic) – US: Novartis files patent infringement suit against Sun Pharmaceuticals in response to Para IV challenge (Patent Docs)

Remicade (Infliximab) – Korea: Celltrion announces Korean approval of biosimilar monoclonal antibody (Beeser Law Professional Corporation)

Tobi Podhaler (Tobramycin) – Canada: Tobramycin patent listing – Federal Court confirms strict product specificity: Novartis v Minister of Health (Beeser Law Professional Corporation)

Viread (Tenofovir) – Thailand: Gilead patents relating to dosage, formulation and combinations challenged in Thailand (IP Komodo)